• J Clin Pharm Ther · Aug 2014

    Review Meta Analysis

    Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials.

    • H Fan, W Yu, Q Zhang, H Cao, J Li, J Wang, Y Shao, and X Hu.
    • Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China.
    • J Clin Pharm Ther. 2014 Aug 1;39(4):334-42.

    What Is Known And ObjectiveGabapentin has been used for the management of post-herpetic neuralgia (PHN). However, inconsistent results have been reported. This meta-analysis was performed to assess the efficacy and safety of gabapentin 1800 mg/day in PHN patients by conducting a meta-analysis.MethodsElectronic databases were searched for relevant randomized controlled trials (RCTs) that compared gabapentin 1800 mg/day to placebo for PHN. The primary outcomes were reduction in 24-h average pain intensity scores, 50% and 30% pain intensity reduction and gabapentin-related side effects. The secondary outcomes were reduction in sleep rating scores and improvement in Patient Global Impression of Change (PGIC) or Clinician Global Impression of Change (CGIC).Results And DiscussionSix RCTs were included. Gabapentin 1800 mg/day reduced the 24-h average pain intensity scores [standard mean differences (SMD) -0·50; 95% confidence interval (CI) -0·88, -0·13; I(2)  = 86·3%] and average daily sleep rating scores [weighted mean differences (WMD) -0·71; 95% CI -1·11, -0·32; I(2)  = 0%]. Gabapentin treatment yielded an improvement in pain intensity (risk ratio (RR) 1·88; 95% CI 1·35, 2·29; I(2)  = 64·8%; for 50% reduction and RR 1·43; 95% CI 1·12, 1·83; I(2)  = 0% for 30% reduction, respectively), PGIC (RR 1·49; 95% CI 1·28, 1·74; I(2)  = 0%), and CGIC (RR 1·58; 95% CI 1·29, 1·92; I(2)  = 30·9%). However, gabapentin increased the somnolence (RR 2·03; 95% CI 1·39, 2·98; I(2)  = 2%), dizziness (RR 2·68; 95% CI 1·95, 3·69; I(2)  = 15%), peripheral oedema (RR 9·10; 95% CI 3·23, 25·60; I(2)  = 2%), total adverse effects (RR 1·28; 95% CI 1·16, 1·42; I(2)  = 0%) and withdrawal due to adverse events (RR 1·51; 95% CI 1·06, 2·16; I(2)  = 6%), but these adverse effects were often mild to moderate.What Is New And ConclusionTreatment with gabapentin 1800 mg/day yielded a significant reduction in PHN up to 14 weeks. Gabapentin 1800 mg appeared safe in treating PHN for up to 24 weeks.© 2014 John Wiley & Sons Ltd.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…